Januvia holds off SGLT2s to keep Merck's Q2 in line - FiercePharma
FiercePharmaJanuvia holds off SGLT2s to keep Merck's Q2 in lineFiercePharmaMerck's diabetes powerhouse Januvia isn't going anywhere in the face of stepped-up competition from Eli Lilly and Boehringer Ingelheim's standout Jardiance, the pharma giant has said.
DPP IV Inhibitors - PR Newswire (press release)
DPP IV InhibitorsPR Newswire (press release)II-10 Select Approved DPP-4 Inhibitors Available in Developed Markets II-11 Januvia - The Leading DPP-IV Inhibitor Drug Worldwide II-11 Galvus Sales Garner Significant Growth II-12 A Comparison of Januvia and Galvus II-12 Pharmacological Comparison .
Shocked! Mylan, Biotechs Swoon After Hillary's Statement - Seeking Alpha
Shocked! Mylan, Biotechs Swoon After Hillary's StatementSeeking AlphaBlockbuster diabetes remedies such as Januvia with no proven health outcomes benefit for thousands of dollars per year, year after year? These have seen immense price increases over the years with few if any technological improvements in their delivery .
The candidates agree: Legalize personal imports of prescription drugs - The Hill (blog)
The Hill (blog)The candidates agree: Legalize personal imports of prescription drugsThe Hill (blog)For many, these include maintenance medications for chronic conditions, such as Januvia for diabetes, Advair Diskus for COPD and Abilify for people battling depression.
Diabetes, Obesity Therapeutics Market Value Will More Than Double By 2022 - Drug Discovery & Development
Drug Discovery & DevelopmentDiabetes, Obesity Therapeutics Market Value Will More Than Double By 2022Drug Discovery & DevelopmentAlthough current top-selling drugs such as Januvia, Novolog and Invokana are expected to remain dominant within the disease cluster, four of the anticipated top 10 best-selling drugs of 2022 will be new to market.